1. Iida A, Kuranuki A, Yamamoto R, Uchida M, Ohta M, Ichimura M, Tsuneyama K, Masaki T, Seike M, Nakamura T. Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM mice. Experimental Animals, 2019: 68, No.4, 417-428.
2. Fukuda A, Sasao M, Asakawa E, Narita S, Hisano M, Suruga K, Ichimura M, Tsuneyama K, Tanaka K, Omagari K. Dietary fat, cholesterol, and cholic acid affect the histopathologic severity of nonalcoholic steatohepatitis in Sprague-Dawley rats. Pathology, Research and Practice 215(11): 152599, 2019.
3. Omagari K, Asakawa E, Sasao M, Narita S, Hisano M, Fukuda A, Suruga K, Ichimura M, Tsuneyama K. Age-related alterations of nonalcoholic steatohepatitis in Sprague-Dawley rats fed a high-fat and high-cholesterol diet. Journal of Nutritional Science and Vitaminology, 65, (4): 349-356, 2019.
3. Omagari K, Asakawa E, Sasao M, Narita S, Hisano M, Fukuda A, Suruga K, Ichimura M, Tsuneyama K. Age-related alterations of nonalcoholic steatohepatitis in Sprague-Dawley rats fed a high-fat and high-cholesterol diet. Journal of Nutritional Science and Vitaminology, 65, (4): 349-356, 2019.
4. Kageyama C, Igawa T, Gion Y, Iwaki N, Tabata T, Tanaka T, Kondo E, Sakai H, Tsuneyama K, Nomoto K, Noguchi H, Yoshino T, Yokota K, Sato Y. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome). Pathology International, Vol.69, No.10, 572-579, 2019.
5. Terziroli BBP, Mieli-Vergani G, Vergani D, Vierling MJ, Adams D, Alpini G, Banales MJ, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, Gottardi De A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley ME, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin EM. The challenges of primary biliary cholangitis: What is new and what needs to be done.Journal of Autoimmunity, Vol.105, 2019.
6. Jia R, Oda S, Tsuneyama K, Urano Y, Yokoi T. Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism. Journal of Applied Toxicology : JAT, 2019.
7. Yang F, Takeuchi T, Tsuneyama K, Yokoi T, Oda S. Experimental Evidence of Liver Injury by BSEP-Inhibiting Drugs With a Bile Salt Supplementation in Rats. Toxicological Sciences, Vol.170, No.1, 95-108, 2019.
8. Takahashi T, Ichikawa H, Morimoto Y, Tsuneyama K, Hijikata T. Inhibition of EP2/EP4 prostanoid receptor-mediated signaling suppresses IGF-1-induced proliferation of pancreatic cancer BxPC-3 cells via upregulating γ-glutamyl cyclotransferase expression.,Biochemical and Biophysical Research Communications, Vol.516, No.2, 388-396, 2019.
9. Takikawa A, Usui I, Fujisaka S, Tsuneyama K, Okabe K, Nakagawa T, Nawaz A, Kado T, Jojima T, Aso Y, Hayakawa Y, Yagi K, Tobe K. Macrophage-specific hypoxia-inducible factor-1α deletion suppresses the development of liver tumors in high-fat diet-fed obese and diabetic mice. Journal of Diabetes Investigation, Vol.10, No.6, 1411-1418, 2019.
10. Kurano M, Tsuneyama K, Morimoto Y, Nishikawa M, Yutaka Yatomi. Apolipoprotein M suppresses the phenotypes of IgA nephropathy in hyper-IgA mice.The FASEB journal, Vol.33, No.4, 5181-5195, 2019.
11. Izawa-Ishizawa Y, Imanishi M, Zamami Y, Hiroki T, Tomoko N, Morishita M, Tsuneyama K, Horinouchi Y, Kihira Y, Takechi K, Ikeda Y, Tsuchiya K, Yoshizumi M, Tamaki T, Ishizawa K. Development of a novel aortic dissection mouse model and evaluation of drug efficacy using in-vivo assays and database analyses. Journal of Hypertension, Vol.37, No.1, 73-83, 2019.
6. Jia R, Oda S, Tsuneyama K, Urano Y, Yokoi T. Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism. Journal of Applied Toxicology : JAT, 2019.
7. Yang F, Takeuchi T, Tsuneyama K, Yokoi T, Oda S. Experimental Evidence of Liver Injury by BSEP-Inhibiting Drugs With a Bile Salt Supplementation in Rats. Toxicological Sciences, Vol.170, No.1, 95-108, 2019.
8. Takahashi T, Ichikawa H, Morimoto Y, Tsuneyama K, Hijikata T. Inhibition of EP2/EP4 prostanoid receptor-mediated signaling suppresses IGF-1-induced proliferation of pancreatic cancer BxPC-3 cells via upregulating γ-glutamyl cyclotransferase expression.,Biochemical and Biophysical Research Communications, Vol.516, No.2, 388-396, 2019.
9. Takikawa A, Usui I, Fujisaka S, Tsuneyama K, Okabe K, Nakagawa T, Nawaz A, Kado T, Jojima T, Aso Y, Hayakawa Y, Yagi K, Tobe K. Macrophage-specific hypoxia-inducible factor-1α deletion suppresses the development of liver tumors in high-fat diet-fed obese and diabetic mice. Journal of Diabetes Investigation, Vol.10, No.6, 1411-1418, 2019.
10. Kurano M, Tsuneyama K, Morimoto Y, Nishikawa M, Yutaka Yatomi. Apolipoprotein M suppresses the phenotypes of IgA nephropathy in hyper-IgA mice.The FASEB journal, Vol.33, No.4, 5181-5195, 2019.
11. Izawa-Ishizawa Y, Imanishi M, Zamami Y, Hiroki T, Tomoko N, Morishita M, Tsuneyama K, Horinouchi Y, Kihira Y, Takechi K, Ikeda Y, Tsuchiya K, Yoshizumi M, Tamaki T, Ishizawa K. Development of a novel aortic dissection mouse model and evaluation of drug efficacy using in-vivo assays and database analyses. Journal of Hypertension, Vol.37, No.1, 73-83, 2019.
12. Okazaki H, Satou S, Koyama K, Morizumi S, Abe S, Azuma M, Chen Y, Goto H, Aono H, Ogawa H, Kagawa K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Kouji H, Nishioka Y. The novel inhibitor PRI-724 for Wnt/β-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice. Experimental Lung Research, Vol.45, No.7, 188-199, 2019.
13. Koyama K, Goto H, Morizumi S, Kagawa K, Nishimura H, Satou S, Kawano H, Toyoda Y, Ogawa H, Homma S, Nishioka Y. The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology, Vol.60, No.4, 478-487, 2019.